Researchers conducted a small, early-stage study to see if a new drug combination could help patients with muscle-invasive bladder cancer who cannot take the standard chemotherapy before surgery. The study involved 49 patients at a single hospital in Italy. All patients received four cycles of two drugs—pembrolizumab and sacituzumab govitecan—before their planned surgery. After this treatment, doctors performed follow-up tests to check for any remaining cancer.
After a median follow-up of 14 months, 19 out of the 49 patients (39%) had a clinical complete response. This means their follow-up scans and tissue samples showed no signs of viable cancer. All 19 of these patients remained free of cancer that had spread. However, two of them later developed a new tumor within the bladder itself.
Regarding safety, 16% of patients experienced a severe but treatable side effect related to the drugs, most commonly diarrhea. There were no deaths from the treatment. The main reason to be careful with these results is that this was a small, single-arm, phase 2 study. There was no comparison group receiving a different treatment, so we cannot yet say if this combination is better than other options. Readers should view this as a hopeful first step that needs confirmation in larger, more definitive trials.